CIK 0001816736 · Large accelerated filer
Disc Medicine, Inc.
Sign in to watch- Ticker
- IRON
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 851612845
- Phone
- (617) 674-9274
- Business address
- 321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
- Former names
- Gemini Therapeutics, Inc. /DE, FS Development Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $14,489,047
- in 7 filings, $12.6M under 10b5-1 plans
Net −$14,489,047. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-10 | Franchi Jean M. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +25,500 | 25,500 | ||
| 2026-02-10 | Quisel John D Chief Executive Officer | Grant or award | +55,200 | 239,328 | ||
| 2026-02-10 | Quisel John D Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +82,800 | 82,800 | ||
| 2026-01-20 | Khara Rahul Chief Legal Officer | Option exercise 10b5-1 | +1,000 | $13.50 | $14K | 38,793 |
| 2026-01-20 | Khara Rahul Chief Legal Officer | Sale 10b5-1 | −1,000 | $69.74 | $70K | 37,793 |
| 2026-01-20 | Khara Rahul Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000 | 21,270 | ||
| 2026-01-02 | Khara Rahul Chief Legal Officer | Option exercise 10b5-1 | +6,500 | $13.50 | $88K | 44,293 |
| 2026-01-02 | Khara Rahul Chief Legal Officer | Sale 10b5-1 | −350 | $77.67 | $27K | 43,943 |
| 2026-01-02 | Khara Rahul Chief Legal Officer | Sale 10b5-1 | −4,993 | $78.62 | $393K | 38,950 |
| 2026-01-02 | Khara Rahul Chief Legal Officer | Sale 10b5-1 | −1,157 | $79.27 | $92K | 37,793 |
| 2026-01-02 | Khara Rahul Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,500 | 22,270 | ||
| 2025-12-22 | Savage William Jacob Chief Medical Officer | Option exercise | +2,825 | $9.86 | $28K | 78,527 |
| 2025-12-22 | Savage William Jacob Chief Medical Officer | Option exercise | +219 | $9.86 | $2K | 78,746 |
| 2025-12-22 | Savage William Jacob Chief Medical Officer | Option exercise | +99 | $13.50 | $1K | 78,845 |
| 2025-12-22 | Savage William Jacob Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −2,825 | 3,550 | ||
| 2025-12-22 | Savage William Jacob Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −219 | 2,628 | ||
| 2025-12-22 | Savage William Jacob Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −99 | 29,905 | ||
| 2025-12-19 | Quisel John D Chief Executive Officer | Option exercise | +12,300 | $1.01 | $12K | 184,128 |
| 2025-12-19 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −12,300 | 186,120 | ||
| 2025-12-17 | Bitterman Kevin Director | Sale | −393 | $91.47 | $36K | 349,210 |
Page 7 of 17 · 337 trades